Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Jay Olson – Oppenheimer Steven Seedhouse – Raymond James Joe Pantginis – H.C. Wainwright Scott Henry – ROTH Capital Yale Jen – Laidlaw & Company Andy Hsieh – William Blair Justin Zelin – BTIG Operator Good day and welcome to the Viking Therapeutics 2022 First Quarter Financial Results Conference Call.

Viking Therapeutics' (VKTX) CEO Brian Lian on Q1 2022 Results - Earnings Call

Conference call scheduled for 4:30 p.m. ET today Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22    Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Results Expected by Year-End  Quarter-End Cash Balance of $185M Provides Runway Through Multiple Clinical Catalysts SAN DIEGO , April 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Conference Call Scheduled for Wednesday, April 27 at 4:30 p.m. Eastern Time SAN DIEGO , April 20, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2022, after the market close on Wednesday, April 27, 2022.

Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022

SAN DIEGO , April 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 21st Annual Needham Virtual Healthcare Conference.

Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN DIEGO , March 8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will present at two upcoming investor conferences.  Details of the company's participation are as follows: 34th Annual Roth Conference Details: Brian Lian, Ph.D.

Viking Therapeutics to Present at Upcoming Investor Conferences

Intercept Pharma

Vir Biotechnology

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

3 Biotech Stocks That Are too Cheap to Ignore

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended December 31, 2021, and Other Recent Events: "The past year was a productive time for Viking as we continued to make progress with our two most advanced clinical programs and further expanded our clinical pipeline with the addition of an important new program," said Brian Lian, Ph.D.

Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 7, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference.

Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2021, after the market close on Wednesday, February 9, 2022. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA

The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.

Why Viking Therapeutics Stock Got Mashed on Monday

The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) fell by over 14% during intraday trading today. This is why it happened.

Viking Therapeutics Stock (VKTX): Why The Price Substantially Went Down Today

The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).  The FDA has requested an additional preclinical study before continuing the Phase 1b study of VK0214 in X-ALD, not due to any findings from ongoing or previously completed studies.

Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder

SAN DIEGO , Jan. 24, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the United States Food and Drug Administration (FDA).  The FDA has requested an additional preclinical study prior to continuing the Phase 1b study of VK0214 in X-ALD.

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is in development for the potential treatment of various metabolic disorders.

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist

CRISPR Therapeutics

Ultragenyx Pharmaceutical

Marinus Pharmaceuticals

Relmada Therapeutics Inc

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C.

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 24.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Viking Therapeutics, Inc. (VKTX)

The average of price targets set by Wall Street analysts indicates a potential upside of 225.8% in Viking Therapeutics, Inc. (VKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Viking Therapeutics, Inc. (VKTX) Could Surge 226%: Read This Before Placing a Bet

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2021 Virtual Healthcare Conference.

Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Viking Therapeutics, Inc. (VKTX) Now Trades Above Golden Cross: Time to Buy?

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended September 30, 2021 and Other Recent Events: "The third quarter was a busy and productive time for Viking as we continued to make progress with our lead clinical programs targeting NASH and X-ALD, and expanded our pipeline with an additional program for metabolic disorders," stated Brian Lian, Ph.D.

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

The consensus price target hints at a 204.1% upside potential for Viking Therapeutics, Inc. (VKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Viking Therapeutics Stock (VKTX)